|
RUNDC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.55290000000996E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.037700E-04 |
| Normal-vs-Stage2 |
5.947800E-01 |
| Normal-vs-Stage3 |
3.03350000008251E-07 |
| Normal-vs-Stage4 |
1.05669999972413E-07 |
| Stage1-vs-Stage2 |
4.482500E-03 |
| Stage1-vs-Stage3 |
9.999400E-04 |
| Stage1-vs-Stage4 |
4.355100E-04 |
| Stage2-vs-Stage3 |
2.19679999999833E-05 |
| Stage2-vs-Stage4 |
3.76469999996409E-06 |
| Stage3-vs-Stage4 |
4.422400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.53499999991469E-07 |
| Normal-vs-AfricanAmerican |
3.706100E-02 |
| Normal-vs-Asian |
5.395200E-03 |
| Caucasian-vs-AfricanAmerican |
3.729400E-01 |
| Caucasian-vs-Asian |
3.501400E-01 |
| AfricanAmerican-vs-Asian |
8.781800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.21490000004609E-06 |
| Normal-vs-Female |
7.96350000000778E-05 |
| Male-vs-Female |
6.641800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.447900E-04 |
| Normal-vs-Age(41-60Yrs) |
5.80689999999384E-05 |
| Normal-vs-Age(61-80Yrs) |
3.92359999999981E-05 |
| Normal-vs-Age(81-100Yrs) |
1.343600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.387400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.478590E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.704000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.464200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.674200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.407400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.00630000005242E-07 |
| Classical-VS-Follicular |
4.140200E-02 |
| Classical-VS-Other |
2.943600E-01 |
| Classical-VS-Normal |
3.98580000000592E-05 |
| Tall-VS-Follicular |
2.98240000473626E-08 |
| Tall-VS-Other |
2.640200E-01 |
| Tall-VS-Normal |
6.31270036244302E-10 |
| Follicular-VS-Other |
1.312160E-01 |
| Follicular-VS-Normal |
5.535700E-02 |
| Other-VS-Normal |
2.229900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.356920E-03 |
| Normal-vs-N1 |
2.62609999968078E-07 |
| N0-vs-N1 |
8.639900E-04 |
|
|
